398 related articles for article (PubMed ID: 28257591)
1. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
[TBL] [Abstract][Full Text] [Related]
2. The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities.
Cortesi PA; Belli LS; Facchetti R; Mazzarelli C; Perricone G; De Nicola S; Cesana G; Duvoux C; Mantovani LG; Strazzabosco M;
J Viral Hepat; 2018 Jul; 25(7):791-801. PubMed ID: 29406608
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.
Vitale A; Spolverato G; Burra P; De Feo TM; Belli L; Donato F; Baroni GS; Marianelli T; Picciotto A; Toniutto P; Bhoori S; Passigato N; Lucà MG; Russo FP; Cillo U; Fagiuoli S;
Transpl Int; 2015 Sep; 28(9):1055-65. PubMed ID: 25865602
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.
Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DMS; Chung RT; Chhatwal J
Clin Gastroenterol Hepatol; 2018 Jan; 16(1):115-122.e10. PubMed ID: 28634131
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
8. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.
Younossi Z; Blissett D; Blissett R; Henry L; Younossi Y; Beckerman R; Hunt S
Liver Int; 2018 Feb; 38(2):258-265. PubMed ID: 28719013
[TBL] [Abstract][Full Text] [Related]
9. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.
Chhatwal J; Samur S; Kues B; Ayer T; Roberts MS; Kanwal F; Hur C; Donnell DM; Chung RT
Hepatology; 2017 Mar; 65(3):777-788. PubMed ID: 27906468
[TBL] [Abstract][Full Text] [Related]
10. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
Njei B; McCarty TR; Fortune BE; Lim JK
Aliment Pharmacol Ther; 2016 Nov; 44(10):1090-1101. PubMed ID: 27640785
[TBL] [Abstract][Full Text] [Related]
11. The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis: A Cost-Effectiveness Analysis.
Tapper EB; Hughes MS; Buti M; Dufour JF; Flamm S; Firdoos S; Curry MP; Afdhal NH
Transplantation; 2017 May; 101(5):987-995. PubMed ID: 27495755
[TBL] [Abstract][Full Text] [Related]
12. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.
Gambato M; Lens S; Navasa M; Forns X
J Hepatol; 2014 Nov; 61(1 Suppl):S120-31. PubMed ID: 25443340
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective.
Kaplan DE; Serper M; Kaushik A; Durkin C; Raad A; El-Moustaid F; Smith N; Yehoshua A
J Manag Care Spec Pharm; 2022 Oct; 28(10):1138-1148. PubMed ID: 36125059
[No Abstract] [Full Text] [Related]
14. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
Salazar J; Saxena V; Kahn JG; Roberts JP; Mehta N; Volk M; Lai JC
Transplantation; 2017 May; 101(5):1001-1008. PubMed ID: 27926593
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
[TBL] [Abstract][Full Text] [Related]
17. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
[TBL] [Abstract][Full Text] [Related]
18. Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.
Park H; Wang W; Henry L; Nelson DR
Hepatology; 2019 Mar; 69(3):1032-1045. PubMed ID: 30289989
[TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection.
Nguyen J; Barritt AS; Jhaveri R
J Pediatr; 2019 Apr; 207():90-96. PubMed ID: 30738661
[TBL] [Abstract][Full Text] [Related]
20. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.
Flemming JA; Kim WR; Brosgart CL; Terrault NA
Hepatology; 2017 Mar; 65(3):804-812. PubMed ID: 28012259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]